Almirall surpassed €1.11 billion in net sales for 2025, driven by tripled revenue from its eczema treatment Ebglyss, which captured €110.8 million in European markets. The Barcelona-based dermatology firm reported a 12.5% revenue increase, with Ebglyss expanding its footprint across Europe after securing approval for moderate-to-severe atopic dermatitis. CEO Carlos Gallardo emphasized the company’s focus on biologics like Ilumetri (psoriasis) and Ebglyss, calling them pivotal to Almirall’s growing influence in skin health.

Ebglyss’s third-year sales surge—up 200% year-on-year—reflects strong demand as the biologic scales production. Almirall aims for €450 million in European sales for the drug, requiring near-quadrupling current levels. Meanwhile, Ilumetri’s net sales rose 12.3% to €234.4 million, though profit margins dipped slightly due to licensing terms. Gross profit climbed 11.9% to €713.3 million, while EBITDA jumped 21% to €232.9 million, underscoring Almirall’s profitability despite margin pressures.

The company’s dermatology portfolio expanded further, with topical psoriasis treatment Wynzora (+30.5%) and skin cancer therapy Klisyri (+33.9%) contributing to a 25.6% rise in European dermatology sales. Almirall also advanced three Phase II studies, including treatments for hidradenitis suppurativa and alopecia areata, signaling robust R&D momentum. With net debt-to-EBITDA at 0x, the firm maintains financial flexibility as it targets 9-12% net sales growth in 2026.

Gallardo highlighted Almirall’s strategic confidence: “Our biologics are the foundation for long-term impact on patients.” The company’s pipeline includes an anti-IL-21 antibody for hidradenitis suppurativa and new approvals for eczema and fungal infections. As Ebglyss reshapes treatment paradigms, Almirall’s €1B+ revenue milestone cements its position as a leader in medical dermatology.